Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139906
Status:
COMPLETED
Last Update Posted:
2015-01-16
First Post:
2005-08-30
Brief Title:
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2006-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to assess the safety and tolerability of a five-day titration schedule using twice daily dosing for the first three days to achieve the highest proposed dose of 40 mg daily The study duration is two months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None